Testosterone and Neural Function - Trial NCT06130449
Access comprehensive clinical trial information for NCT06130449 through Pure Global AI's free database. This Phase 1 trial is sponsored by VA Office of Research and Development and is currently Not yet recruiting. The study focuses on Spinal Cord Injury. Target enrollment is 15 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
VA Office of Research and Development
Timeline & Enrollment
Phase 1
Apr 01, 2024
Mar 31, 2026
Primary Outcome
Electromyographic responses
Summary
Spinal cord injury (SCI) disrupts the nerves controlling movement, along with those that
 regulate functions like heart rate and blood pressure (known as the autonomic nervous system,
 or ANS). Testosterone (T) plays a significant role in brain health and ANS reflex function in
 non-neurologically impaired men. However, little is known about the relationships between T,
 nerve function, and ANS dysfunction after SCI. Interestingly, up to 60% of men with SCI
 exhibit persistently low T concentrations, which may worsen nerve and ANS dysfunction. In
 uninjured eugonadal people (normal physiologic range of serum T concentrations), a single
 pharmacologic dose of intranasal T has been shown to quickly improve nerve function, but no
 study has evaluated if T administration alters nerve and ANS function in men with SCI.
 Herein, the investigators will conduct the first study to test how a single dose of
 intranasal T impacts motor and ANS function in this population.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06130449
Non-Device Trial